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Purpose: This study assessed the recurrence rate and other safety and efficacy parameters 
following ventral hernia repair with a polyester composite prosthesis (Parietex™ Composite 
Ventral Patch [PCO-VP]).
Patients and methods: A single-arm, multicenter prospective study of 126 patients undergoing 
open ventral hernia repair with the PCO-VP was performed. Patient outcomes were assessed at 
discharge and at 10 days, 1, 6, 12, and 24 months postoperative.
Results: All patients had hernioplasty for umbilical (n = 110, 87.3%) or epigastric hernia (n = 
16, 12.7%). Mean hernia diameter was 1.8 ± 0.8 cm. Mean operative time was 36.2 ±15.6 min-
utes, with a mean mesh positioning time of 8.1 ± 3.4 minutes. Surgeons reported satisfaction 
with mesh ease of use in 95% of surgeries. The cumulative hernia recurrence rate at 1 year was 
2.8% (3/106). Numeric Rating Scale (NRS) pain scores showed improvement from 2.1 ± 2.0 at 
preoperative baseline to 0.5 ± 0.7 at 1 month postoperative (P < 0.001), and this low pain level 
was maintained at 12 months postsurgery (P < 0.001). The mean global Carolina’s Comfort 
Scale® (CCS) score improved postoperatively from 3.8 ± 6.2 at 1 month to 1.6 ± 3.5 at 6 months 
(P < 0.001). One patient was unsatisfied with the procedure.
Conclusion: This 1-year interim analysis using PCO-VP for primary umbilical and epigastric 
defects shows promising results in terms of mesh ease of use, postoperative pain, and patient 
satisfaction. Recurrence rate is low, but, as laparoscopic evaluation shows a need for patch 
repositioning in some cases, an accurate surgical technique remains of utmost importance.
Keywords: intraperitoneal mesh, epigastric hernia, umbilical hernia, pain
Plain language summary
A hernia is the protrusion of bowel or fat through a weakness in the abdominal wall. Small 
ventral hernias can occur at the navel or upper part of the abdomen. These small hernias are 
treated by surgical repair and implantation of a mesh textile for abdominal wall support; however, 
placement and fixation of the mesh implant can be technically challenging. The device used in 
this study was designed to assist in these challenges; it contains removable handles for proper 
mesh positioning, four mesh flaps for suture fixation, and an absorbable expander to facilitate 
mesh deployment. This study followed up >100 hernia repair patients for 1 year to assess patient 
complications and hernia recurrence after repair with the device. Thus far, patients reported 
experiencing low pain and complication rates within 1 year after their repair, and three patients 
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had a hernia recurrence. These results suggest that the device is 
effective for most patients within the first year of implantation.
Introduction
Primary umbilical and epigastric hernias exhibit recurrence 
rates of up to 16% following suture repair.1 Clinical studies 
have demonstrated the advantage of mesh hernioplasty over 
suture repair, even for small midline hernias of 1–3 cm.2–4 
Retrorectus and preperitoneal dissection for these small 
hernias can be technically difficult. Self-expanding mesh 
devices can be introduced through the defect into the peri-
toneal cavity through an incision at the level of the hernia. 
After self-deployment of the device, traction on the fixation 
points or straps should achieve appropriate and flat place-
ment posterior to the hernia defect. These devices have been 
embraced by many surgeons as a quick and elegant technique.
Two popular polypropylene (PP) devices have different 
tissue separating barriers. One has an ePTFE patch sewn to 
PP as an antiadhesive barrier, and the other is a nine-layer 
composite mesh with oxidized cellulose as an antiadhesive 
barrier. However, clinical studies of both devices have 
revealed cases of inadequate deployment, serious complica-
tions, and higher recurrence rates compared to traditional 
retromuscular mesh placement.5–7 To solve the problems of 
both inadequate deployment and flat alignment to the abdomi-
nal wall, a device containing a dual-facing three-dimensional 
monofilament polyester mesh was introduced. The device 
includes four flaps for fixation, instead of the two fixation 
points on other available mesh devices.
This PANACEA study is a 24-month international non-
comparative prospective study of patients undergoing open 
ventral hernia repair with intraperitoneal positioning of 
Parietex™ Composite Ventral Patch (PCO-VP). The 1-year 
results of all 126 enrolled patients are presented in this article.
Patients and methods
This study was conducted in accordance with the Declara-
tion of Helsinki (2008), the protocol, ICH–GCP guidelines, 
and ISO 14155-2011. Approval of the study protocol and 
amendments, proposed informed consent forms, written 
subject information, and other study-related documents 
were obtained from institutional review boards (IRBs) and 
independent ethics councils (ECs) for each investigational 
site. These ECs and IRBs were Central Ethic Committee: 
Ethisch Comité UZ Gent (site 1), VZW (nonprofit orga-
nization) AZ Maria Middelares Hospital Ethisch Comité 
(site 2), WZV den Olm (nonprofit organization) Imelda 
Hospital: Bonheiden Medisch Ethisch Comité (site 3), Region 
Hovedstafden Koncern Organization og Personale, De Viden 
Skasetiske Komiteer 3400 Hillerod (site 4), METC Medical 
Ethics Review Committee: CCMO Central Committee on 
Research Involving Human Subjects (site 5), EPN Regional 
Ethical Review Board in Linköping: Department for Medi-
cal Research Assessment (site 6), PTV Foundation for Tor 
Vergata University Hospital, Rome: Independent Ethic 
Committee (site 7), MO IRB (formerly WIRB and Capital 
Region) (site 8), Western Institutional Review Board (sites 9, 
10, and 12), and Monmouth IRB (site 11). Written informed 
consent was obtained from subjects before any study-specific 
activity was performed and at the time of enrollment in the 
study. The study was registered publically at clinicaltrials.
gov (NCT01848184).
Trial design and objective
In this prospective international multicenter noncompara-
tive cohort study, patients underwent small primary ventral 
hernia repair with intraperitoneal PCO-VP positioning. The 
objectives were to assess hernia recurrence at 24 months 
follow-up, safety, and feasibility.
Test device
PCO-VP (Medtronic, Trevoux, France) is a dual-facing mesh 
composed of a nonabsorbable three-dimensional monofila-
ment polyester textile for abdominal wall reinforcement. It 
has a bioabsorbable hydrophilic collagen film to minimize 
visceral attachment, absorbable expanders to facilitate 
proper placement, and a fixation system with four flaps and 
two removable handles. PCO-VP is indicated for repair of 
primary ventral defects and is available with an 8.6, 6.6, or 
4.6 cm diameter.
Participants
Consented patients aged ≥18 years scheduled for primary 
ventral hernia repair via open approach were assessed for 
eligibility via a screening/baseline visit within 6 weeks of 
their procedure. Patients who required emergency surgery, 
were participating in other trials, were pregnant, had a his-
tory of hernia at the same location of repair, had a body 
mass index (BMI) >35 kg/m2, had an American Society of 
Anesthesiologist score ≥4, or were unable to comply with 
follow-up visits were excluded.
Operative technique
General anesthesia was administered, at which time patients 
received one dose of intravenous antibiotics according to hos-
pital practice. After opening the hernia sac, the fascial defect 
was measured to ensure sufficient mesh overlap. For very 
small defects, the surgeon was allowed to increase the fascial 
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gap by ≤0.5 cm to facilitate mesh introduction. For hernias 
<1 cm in diameter, any size of PCO-VP was recommended. 
For hernias 1–3 cm in diameter, 6.6 and 8.6 cm PCO-VP were 
recommended, and for hernias >3 cm in diameter, 8.6 cm 
PCO-VP was recommended. Patients with fascial defect 
diameter >4 cm were withdrawn from the study. Devices 
were deployed in the intraperitoneal position according to 
the instructions for use. Four double-armed nonresorbable or 
slowly resorbable stitches were applied for fixation. Follow-
ing skin closure, the surrounding muscle tissue, subcutane-
ous tissue, and dermis were infiltrated with local anesthetic. 
Final mesh placement was examined by laparoscopy with a 
5 mm trocar in 10 patients at the Ghent University Hospital 
site. Surgical repositioning to obtain satisfactory alignment 
of the mesh was recorded.
Clinical assessments were performed at discharge, 1-, 
6-, 12-, and 24-month follow-ups. Follow-up at 10 days was 
done by telephone.
Outcomes measures
The primary end point, recurrence at 24 months, was not 
assessed in this interim evaluation. The secondary end points 
were recurrence at 1 month (-1 and +2 weeks), 6 months 
(±4 weeks), and 12 months (-1 and +4 weeks) as diagnosed 
during a physical examination and confirmed by ultraso-
nography. Additional outcomes included 1) postoperative 
pain measured by the Numeric Rating Scale (NRS) 0–10 
and compared to baseline values; 2) postoperative patient 
comfort measured by the Carolina’s Comfort Scale® (CCS) 
(range: 0–115) calculated by the sum of sensation, pain, and 
movement scores; 3) accurate mesh alignment by laparo-
scopic exam in n = 10 patients; and 4) adverse events (AEs).
Statistics
End points were represented by descriptive measures, and 
the sample size was determined by material, calendar, 
and site-recruitment constraints, and precision of mea-
sures and estimations desired. The recurrence rate for 
primary ventral hernia repair using synthetic mesh is ~4% 
(range: 0%–6%).6,8–11 Assuming a 95% confidence interval 
and 4% recurrence (±5% precision), N = 60 patients were 
needed for the evaluable population. Anticipating a 20% 
lost to follow-up rate at both 12 and 24 months, a minimum 
of 100 patients were required as the evaluable population.
Data were summarized by counts, mean values, standard 
deviations, medians, minimum, and maximum (for continu-
ous variables) or frequencies and percentages (for categorical 
variables). Recurrence rates and complications were analyzed 
on global follow-up and using time to event (Kaplan–Meier) 
analysis. Mean comparisons between subgroups were run 
using Student’s t-test or nonparametric Mann–Whitney 
U-test. Proportion comparisons between subgroups were 
performed using chi-square or Fisher’s exact test. All com-
parisons and tests were performed using two-sided tests with 
α-level of 5%. Analyses were performed using SAS® version 
9.2 or higher (SAS Inc., Cary, NC, USA).
Results
Demographics and procedural 
characteristics
A total of 126 patients were enrolled between May 3, 2013, 
and July 10, 2014, at 12 centers in Europe and the US. The 
majority (87.3%) of patients was treated for an umbilical 
hernia, while 12.7% were treated for epigastric hernia 
(Table 1). Mean BMI was 27.6 ± 4.4 kg/m2, with 34.1% 
Table 1 Patient demographics, comorbidities, and operative 
details, N = 126
Age (years) 51.2 ± 12.2
Gender
Female 39 (31.0)
Male 87 (69.0)
BMI, kg/m2 27.6 ± 4.4
<30 83 (65.9)
≥30 43 (34.1)
Hernia type
Umbilical 110 (87.3)
Epigastric 16 (12.7)
Subjects with at least one risk factor 90 (71.4)
Smoker (current or prior) 54 (42.9)
Obesity (BMI ≥30 kg/m2) 43 (34.1)
Diabetes type II 10 (7.9)
COPD 9 (7.1)
Stable disease 6 (66.7)
Chronic disease requiring analgesic consumption 2 (1.6)
Chronic disease requiring corticoid consumption 3 (2.4)
Other disease leading to increased abdominal pressure
Benign prostatic hypertrophy 1 (0.8)
Liver cirrhosis/ascites/liver transplantation 2 (1.6)
Mean hernia diameter, cm 1.8 ± 0.8
Overlap, cm
<1 1 (0.8)
1.0–1.9 43 (34.1)
2.0–2.9 71 (56.3)
3.0–4.0 11 (8.7)
Mean ± SD 2.2 ± 0.6
Operative time, min (n = 124) 36.2 ± 15.6
Mesh positioning time, min (n = 124) 8.1 ± 3.4
Hospital length of stay, days
Median 0.0
Min–max 0–2
Notes: Data are presented as n (%), mean ± standard deviation, min–max, or 
median. Overlap = (size of mesh - hernia diameter)/2.
Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary 
disease; SD, standard deviation; min, minimum; max, maximum.
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of patients having a BMI over 30 kg/m2. Risk factors at 
baseline (Table 1) included smoking (42.9%), type II dia-
betes (7.9%), and chronic obstructive pulmonary disease 
(7.1%). Mean operative time was 36.2 ± 15.6 minutes, 
with a mean mesh positioning time of 8.1 ± 3.4 minutes. 
Ninety-six (76.2%) patients were discharged the same day 
as the procedure, 25 (19.8%) patients were discharged after 
1 day, and 5 (4.0%) patients were discharged after 2 days.
Patient disposition and recurrence
One-hundred ten patients were assessed at 12 months 
(Figure 1). Of the 110 patients, 5 were assessed too early 
(according to the protocol for the 12-month visit window) 
and thus were not included in the calculation for recurrence; 
these five patients had no recurrence at their last visit. In 
total, three hernia recurrences occurred within 12 months 
(at 79, 197, and 288 days after surgery), with a 1-year 
cumulative recurrence rate of 2.8% (3/106, including the 
patient with recurrence at 79 days who withdrew from the 
study). Reoperation was performed for the patient with the 
earliest recurrence.
Protocol recommendations for mesh sizes were followed 
for 107/126 (84.9%) patients. All patients who experienced 
recurrence had received the recommended size patch accord-
ing to the hernia diameter (Table 2). There was no significant 
difference between the patch overlap (mesh–hernia diameter) 
in patients with recurrence (mean: 2.6 ± 0.8 cm) versus those 
without recurrence (mean: 2.2 ± 0.6 cm) (P = 0.336).
Pain and quality of life
Postoperative NRS scores are depicted in Figure 2. By day 10 
postoperative, no patients were experiencing severe pain com-
pared to 4 (3.3%) and 5 (4.1%) patients at baseline and dis-
charge, respectively. At baseline and discharge, only 34/120 
(28.3%) and 17/123 (13.8%) patients, respectively, were 
experiencing no pain, which improved to 77/123 (62.6%) 
at 1 month and 93/111 (83.8%) at 12 months. Compared to 
baseline, mean pain scores were reduced significantly (P < 
0.001) at 1, 6, and 12 months (-1.6 ± 2.0, -1.7 ± 1.9, and 
-1.9 ± 1.9, respectively). The mean CCS score was 3.8 ± 
6.2 at 1 month postoperative, and it decreased significantly 
to 1.6 ± 3.5 and 1.4 ± 4.3 (P < 0.001) at 6 and 12 months 
postsurgery, respectively. A vast majority of patients were 
completely satisfied with the procedure at all points of 
assessment (Figure 3).
Mesh placement
Surgeons reported a perioperative assessment of mesh 
manipulability and ease of use and were completely satisfied 
or satisfied with the ease of mesh handling in 120 (95.2%) 
cases. In one (0.8%) case, the surgeon reported complete 
dissatisfaction because the mesh had to be removed twice 
due to uncertain positioning of the device.
A laparoscopic examination was performed in the final 
10 consecutively enrolled patients to assess mesh positioning 
following open repair. Two assessments were made: whether 
the mesh was in flat alignment, which was defined as the mesh 
lying in complete contact with the peritoneum with no spaces, 
and whether the mesh showed cupping, which was defined 
as any kink in the mesh (a so-called potato chip defect). Flat 
alignment was noted in the majority of cases (6/10 [60%] 
patients). Interpositioning of fatty tissue prevented flat align-
ment in two patients (20%), and cupping of the mesh at the 
side of the falciform ligament prevented flat alignment in two 
patients (20%). In these four cases, the mesh position was 
24 months
32 (25.4%)
12 months
110 (87.3%)
6 months
105 (83.3%)
1 month
121 (96.0%)
Operative/discharge
126 (100.0%)
Figure 1 Patient follow-up visit completion.
Notes: The number of patients who successfully completed each visit is shown as 
n (%). Twelve (9.5%) patients withdrew early from the study. Early end-of-study 
reasons included: loss to follow-up (n = 4), adverse event (n = 1), withdrawal by 
subject (n = 6), and patient was unable to participate in follow-up visits (n = 1).
Table 2 Mesh size recommendations and recurrence 
Mesh size, cm
Hernia diameter, cm
<1 1.0–1.9 2.0–2.9 3.0–4.0
4.6 (N = 39) 8 (20.5) 22 (56.4)a 8 (20.5) 1 (2.6) 
6.6 (N = 66) 3 (4.5) 39 (59.1) 18 (27.3) 6 (9.1) 
8.6 (N = 21) 0 (0.0) 1 (4.8) 10 (47.6)a 10 (47.6)a
Notes: Data are presented as n (%). Bold text indicates that the recommended 
mesh size for the corresponding defect size was used. aThe subsets that include a 
patient who exhibited hernia recurrence.
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readjusted once each to achieve a completely flat alignment, 
without necessitating removal of the patch from the defect.
Complications and AEs
Fifty-nine AEs were experienced by 39 (31.0%) patients, 
most (29) of whom had mild or moderate AE. Eighteen 
device-related AE occurred in 16 patients, including three 
serious AE in one patient each (procedural pain, pain due 
to recurrence, and recurrent umbilical hernia). Procedural 
pain was the most common (16 patients; 12.7%) of all 
procedural- and device-related AE (Table 3). One (0.8%) 
patient sustained a nonserious AE of a puncture of the small 
bowel during operation , two (1.6%) patients developed 
incision site hematomas, and two (1.6%) patients developed 
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Figure 2 NRS pain assessment.
Notes: Pain levels were classified based on NRS scores: 0 = no pain, 1–3 = mild pain, 4–6 = moderate pain, and 7–10 = severe pain. (A) Patient pain levels at baseline, 
discharge, day 10, 1-, 6-, and 12-months postoperative. (B) Mean pain levels reported through 12 months. Standard deviation is shown. *P < 0.001 relative to baseline.
Abbreviation: NRS, Numeric Rating Scale.
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Figure 3 Patient satisfaction at 1-, 6-, and 12-months postoperative and last known 
satisfaction for each patient.
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a seroma, all procedure related. Analysis showed no correla-
tion between preoperative risk factors and seroma, wound 
infection, recurrence, or hematoma. Laparoscopic evalu-
ation of a suspected recurrence at 15 months postsurgery 
revealed a preperitoneal lipoma; no recurrence was present. 
One surgeon reported a device malfunction, stating that the 
mesh did not open fully and had to be removed. The fascial 
incision was enlarged by 1.5 cm, and a second mesh was 
deployed. In total, 31 (27.2%) patients had their hernia gap 
enlarged as permitted by protocol to allow smooth introduc-
tion of the PCO-VP.
Discussion
Umbilical and epigastric hernias were historically repaired 
using primarily suture closure. Suture repair or the Mayo 
technique for umbilical hernia closure are both associated 
with a recurrence rate of 10%–30%.12,13 The use of a pros-
thetic mesh, even for small defects, significantly reduces 
hernia recurrence.2,3,14 This 1-year interim analysis of the 
PANACEA trial shows a low 12-month recurrence rate of 
2.8% (3/106). In addition, patients report minimal discomfort 
and high satisfaction following open repair with PCO-VP.
Historically, poor conformability to the parietal perito-
neum has been a challenge, potentially leading to a cupping 
phenomenon or potato chip deformities.5,15 For some devices, 
the origin of these complications seems to be the excessive 
traction on the two straps that need to be pulled in order 
to draw the patch tightly against the parietal peritoneum.16 
Extensive traction results in cupping and deformity of the 
patch that is unnoticed externally by the surgeon and only 
visible by laparoscopic evaluation after patch placement.5,17 
Experimental and clinical studies of other devices have 
shown difficulties and recurrences likely due to extensive 
shrinkage of the different layers of materials in other 
patches.6,15,17
A recent study assessed the prosthetic design of PCO-
VP,18 which includes four mesh flaps, instead of only two 
straps, to aid in positioning and fixation. This design allows 
the patch to be deployed and stretched as much as possible 
by suturing the four flaps to the outer line of the covered 
fascial edges circumferentially. The authors concluded, 
after comparing Ventralex™ ST hernia patch (Bard Davol), 
Proceed® Ventral Patch (Ethicon), and PCO-VP, that both the 
intraperitoneal positioning and the incorporation of the PCO-
VP mesh in the abdominal wall were improved compared to 
the other devices.18 In the case of PCO-VP, the antiadhesive 
collagen barrier seems less prone to intraperitoneal adhe-
sions versus the oxidized regenerated cellulose barrier and 
has already proven its efficacy and safety in preclinical and 
clinical settings.19–21
Within our study, we observed misalignment of the mesh 
in 4 of 10 patients who underwent laparoscopic examination; 
however, the laparoscopic examination included only a small 
sample of our total study population, and thus the true rate 
of misalignment within our study may be lower or higher 
than the 40% observed. 
This study is the first to extensively document clinical data 
for the new PCO-VP. Although not directly comparable due 
to differences in follow-up time and experience of surgeons, 
the observed 2.8% recurrence rate is less than that reported 
previously with use of the Ventralex™ hernia patch (up to 
14.8% in 25 months)5,9,16,22–25 or the Proceed® Ventral Patch 
(up to 12% in 16 months)26–30 or by the regional cohort 
study from the Danish Hernia Database (up to 10% over 
43 months);1 however, it is in line with the results from the 
meta-analysis by Nguyen et al31 showing a 2.7% recurrence 
rate after mesh repair of primary ventral hernias. These initial 
PANACEA study results are reported at 1 year, and a longer 
follow-up is necessary to assess whether this low recurrence 
rate with PCO-VP is maintained long term. Furthermore, as 
this study reports on many patient outcome parameters, all 
possible related complications have been documented herein. 
Historically, wound morbidity has been considered as one 
of the major disadvantages using mesh for repair of small 
umbilical and epigastric hernias. Hernia recurrence is lower 
using mesh but at the cost of a higher rate of wound morbidity 
and mesh infections compared to suture repair.31 Our study 
showed only 4.0% incidence of superficial wound infection, 
Table 3 Procedure- and device-related adverse events, N = 126
Procedural pain 16 (12.7%)
Wound infection 5 (4.0%)
Hernia recurrence 3 (2.4%) 
Postoperative hematoma at the incision site 2 (1.6%) 
Seroma 2 (1.6%)
Abdominal pain due to recurrence 1 (0.8%) 
Constipation 1 (0.8%) 
Fever 1 (0.8%) 
Hemoglobin down versus standard 1 (0.8%) 
Hypotension 1 (0.8%) 
Nausea 1 (0.8%) 
Occasional feeling of tightness at the operative site 1 (0.8%) 
Serous drainage at the incision site 1 (0.8%) 
Skin irritation 1 (0.8%) 
Swelling of left cheek 1 (0.8%) 
Puncture of small bowel 1 (0.8%)
Vaginal bleeding 1 (0.8%)
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with no evidence of mesh infection. Since superficial wound 
infection only rarely leads to mesh infection, and since mesh 
repair of umbilical and epigastric hernias has been shown to 
have lower rates of recurrence than sutured repair, we con-
clude that mesh should be used for the repair of umbilical 
and epigastric hernias of any size, even very small ones of 
<4 cm. Furthermore, these 1-year results revealed no differ-
ences between epigastric and umbilical hernia in terms of 
dissection difficulty, mesh ease of use during the procedure, 
operative time, or incidence of AEs. The ratio of epigastric 
to umbilical hernia repair was, however, 16:110, and thus 
possible differences may not be exposed by our study.
By postoperative day 10, 7.2% of patients were experienc-
ing moderate pain, with the remainder experiencing mild or 
no pain. At 1 month, no patient reported moderate or severe 
pain, a rate maintained at 12 months. These results suggest 
a potentially better outcome than results with the Proceed® 
Ventral Patch, which showed 3.1% (3/96) of patients still had 
moderate or severe pain at 12 months postsurgery;27 however, 
these differences may be due to different fixation methods 
or other study variables. In our study, this excellent patient 
outcome is also reflected in the quality-of-life global CCS 
score, which incorporates the sensation, pain, and movement 
scores. In contrast to results reported by others, only one of 
three patients experienced any pain associated with recur-
rence. Our laparoscopic intraperitoneal evaluations suggest 
that surgical technique using PCO-VP still remains crucial, 
particularly complete dissection of the falciform ligament 
cranially and the umbilical folds caudally to limit interfer-
ence with the patch placement. This seems to be especially 
true for the larger patch of 8.8 cm diameter.
The study is limited by the absence of a control group, 
preventing conclusions about clinical performance of PCO-
VP compared to alternate devices or surgical mesh repair 
techniques. In addition, this interim publication does not 
report sufficient follow-up to draw conclusions about long-
term safety and efficacy.
Conclusion
This closely monitored clinical trial has shown low recur-
rence rates thus far, with very low, and mainly mild mor-
bidity 12 months postsurgery. The mesh device seems 
promising, with high postoperative QOL and excellent 
patient satisfaction.
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